A Phase III Study of Alpha-Interferon Consolidation Following Intensive Chemotherapy with ProMACE- MOPP (Day 1-8) in Patients with Low Grade Malignant Lymphomas

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

Survival by Hispanic Ethnicity Among Cancer Patients participating in SWOG Clinical Trials

A Moseley;M Chavez-MacGregor;J Unger;S Ramsey;D Hershman Society for Clinical Trials Annual Meeting (May 20-23 2018, Portland, OR), oral presentation

Fc gamma receptor 3a genotype predicts overall survival for follicular lymphoma patients treated on Southwest Oncology Group trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

D Persky;D Dornan;B Goldman;R Braziel;R Fisher;M LeBlanc;DG Maloney;OW Press;TP Miller;L Rimsza Haematologica 97(6):937-942

PMid: PMID22271896 | PMC number: PMC3366663

Prognostic value of regulatory T-cells, lymphoma associated macrophages and Mum-11 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study [PMC2875547; PMID19875761]

JW Sweetenham;B Goldman;M LeBlanc;JR Cook;RR Tubbs;OW Press;DG Maloney;RI Fisher;LM Rimsza;ED Hsi Annals of Oncology 21(6):1196-1202;

Fc gamma receptor 3a genotype predicts overall survival for follicular lymphoma patients treated on Southwest Oncology Group trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

DO Persky;D Dornan;B Goldman;M LeBlanc;RM Braziel;RI Fisher;D Maloney;T Miller;OW Press;LM Rimsza Blood 114:abst.#111 (ASH Annual Meeting, oral presentation)

Non-hodgkins lymphoma

R Fisher;P Mauch;J Friedberg;L Rimsza In Cancer: Principles and Practice of Oncology, 8th edition, Lippincott, Williams & Wilkins, Baltimore, MD, pp 2098-2158, 2008

MUM1 expression in follicular lymphoma is a poor prognostic marker in patients treated with immunochemotherapy (SWOG 9800/9911) but not chemotherapy alone (SWOG 8809): A Southwest Oncology Group correlative science study

ED Hsi;B Goldman;LM Rimsza;JR Cook;RR Tubbs;OW Press;DG Maloney;RI Fisher;JW Sweetenham Blood 112(11):146, abst. 376

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

Numbers of lymphoma associated macrophages (LAMS) and regulatory T-cells (Tregs) in follicular lymphoma (FL) patients (pts) treated with and without monoclonal antibody (MoAb)-containing therapy do not correlate with overall survival (OS): a study from the Southwest Oncology Group (SWOG)

JW Sweetenham;E Hsi;B Goldman;M LeBlanc;RR Tubbs;JR Cook;OW Press;RI Fisher;LM Rimsza Blood 110(11):#2602

New treatment options have changed the survival of patients with follicular lymphoma

RI Fisher;M LeBlanc;OW Press;DG Maloney;JM Unger;TP Miller Journal of Clinical Oncology 23(33):8447-8452

Follicular lymphoma international prognostic index

P Solal-Celigny;P Roy;P Colombat;J White;JO Armitage;R Arranz-Saez;WY Au;M Bellei;P Brice;D Caballero;D Coiffier;E Conde-Garcia;C Doyen;M Federico;RI Fisher;JF Garcia-Conde;C Gugliemi;A Hagenbeek;C Haioun;M LeBlanc;AT Lister;A Lopez-Guillermo;P McLaughlin;N Milpied;P Morel;N Mounier;SJ Proctor;A Rohatiner;P Smith;P Soubeyran;H Tilly;U Vitolo;PL Zinzani;E Zucca;E Montserrat Blood 104(5):1258-1265

Interferon alfa consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low -grade non-hodgkin's lymphoma: results of theSouthwest Oncology Group randomized phase III study 8809

RI Fisher;BW Dana;M LeBlanc;C Kjeldsberg;JD Forman;JM Unger;SP Balcerzak;ER Gaynor;V Roy;T Miller Journal of Clinical Oncology 18(10):2010-2016

A randomized study of alpha-interferon consolidation in patients with low-grade lymphoma who have responded to pro-MACE-MOPP (day 1-8) (SWOG 8809).

BW Dana;J Unger;RI Fisher Proc of the American Society of Clinical Oncology 17:3a(#10)

A randomized study of alpha-interferon consolidation in patients with low-grade lymphoma who have responded to pro-MACE-MOPP (day 1-8) (SWOG 8809).

RI Fisher;J Unger;BW Dana Annals of Hematology 77(Suppl.1):A9(#36)